Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Zentalis Pharmaceuticals, with four buys, four holds and one sell among nine analysts. The average 12-month price target is $6.75, versus a recent share price of $3.80.
• Major shareholder Group Walters purchased 4.335 million shares for approximately $15.2 million, increasing its ownership by 32.09%; insiders collectively own 3.8% of the company.
• Zentalis reported a quarterly loss of $0.59 per share, missing the $0.49 analyst consensus, and analysts expect a full-year loss of $2.14 per share. The clinical-stage biotechnology company is developing oncology treatments, including lead candidate ZN-c3.

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.75.

Several research firms have issued reports on ZNTL. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a "buy" rating and a $11.00 target price on the stock. Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an "outperform" rating and a $8.00 target price on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the purchase, the insider directly owned 17,844,973 shares of the company's stock, valued at approximately $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.80% of the company's stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sivia Capital Partners LLC bought a new position in Zentalis Pharmaceuticals during the 4th quarter worth $27,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals during the first quarter valued at $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at $37,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter worth about $41,000. Finally, Spark Investment Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the second quarter worth about $61,000.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $3.80 on Thursday. The company's 50 day simple moving average is $4.33 and its 200-day simple moving average is $3.81. The firm has a market capitalization of $272.35 million, a PE ratio of -1.95 and a beta of 1.85. Zentalis Pharmaceuticals has a 12 month low of $1.21 and a 12 month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.